On June 1 the European Medicines Agency put a rulebook under synthetic peptide manufacturing for the first time. The guideline on the development and manufacture of synthetic peptides ↗ (reference EMA/CHMP/CVMP/QWP/367182/2025) was adopted last December and became legally effective at the start of this month. It was drafted by the agency's Quality Working Party and signed off by both the human-medicines committee, the CHMP, and the veterinary committee, the CVMP. It is the first document the EMA has written that deals only with how these drugs are made, rather than folding them into the general rules for chemical drug substances.
The timing is not an accident. Synthetic peptides are the chemistry behind the biggest drug story of the decade, and the factories making them are running hot.
What the rules actually police
A synthetic peptide is built one amino acid at a time, usually on a solid resin bead, in a process that can run dozens of steps for a single molecule. Each step is a chance to go slightly wrong. The chain can skip a residue and leave a deletion sequence, add an extra one and leave an insertion sequence, or keep a protecting group it was supposed to shed. The result is a batch of the correct peptide salted with closely related wrong ones, called sequence-related impurities. They are hard to separate because they look almost exactly like the real thing, and hard to even see for the same reason.
That is the problem the guideline is built around. It asks manufacturers for a clear, step-by-step account of the synthetic route, whether it uses solid-phase synthesis, solution-phase synthesis, or a hybrid that stitches fragments together, and it sets expectations for characterising and controlling those impurities and any conjugation chemistry. In plain terms, the question it forces is the one that separates a real drug from a knockoff: do you actually know everything that is in the vial, and can you keep it the same batch to batch.
The scope is wide. It covers both new and already-approved synthetic peptide active substances, in human and in veterinary medicines, including post-approval manufacturing changes and peptides used in clinical trials. Recombinant peptides grown in cells and radiopharmaceuticals are carved out, since they live under separate frameworks.
Why the floor is going in now
Demand is the context. On June 15, two weeks after the guideline took effect, France became the first European Union country to put Wegovy and Mounjaro on public reimbursement ↗, covering 65 percent of the cost for patients with severe obesity, joining the United Kingdom and Switzerland outside the bloc. Every covered prescription is more synthetic peptide that has to be made to spec. Around the marketed drugs sits a fast-growing gray market of compounded and research-grade peptides whose purity is exactly what a manufacturing standard is supposed to pin down.
Semaglutide ↗, the molecule in Ozempic and Wegovy, and tirzepatide ↗, the molecule in Mounjaro and Zepbound, are both synthetic peptides assembled by exactly the kind of chemistry the guideline now governs. The peptidemodel cards describe what these molecules do at their receptors. The EMA document is about the layer beneath that: whether the thing in the syringe is the molecule on the card and only that molecule.
This is a quiet regulatory inflection rather than a loud one. No drug was approved or pulled. But it lands during the same stretch that saw Britain clear the Wegovy pill ↗, and it changes the paperwork every European peptide maker now has to produce. The standards for what counts as a clean batch just stopped being implicit.